In this cohort study of 45 631 patients with advanced NSCLC, substantial increases occurred in the use of first-line immune checkpoint inhibitor treatment among patients with low or negative PD-L1 expression and those without documented PD-L1 testing. Here, CD274 is linked to non-small cell lung carcinoma.